Donepezil

Generic Name: Donepezil

Brand Names: Adlarity, Aricept, Namzaric

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₂₉NO_₃

CAS Number: 120014-06-4

Unique Ingredient Identifier: 8SSC91326P

Background: In 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990. Donepezil, also known as Aricept, is a piperidine derivative acetylcholinesterase inhibitor used in the management of the dementia of Alzheimer's Disease, and in some cases, is used to manage other ty...

Indication: Donepezil, administered orally or via transdermal delivery system, is indicated for the treatment of dementia of the Alzheimer's type. It is also available as an extended-release capsule in combination with memantine for the treatment of moderate-to-severe dementia of the Alzheimer's type in patients previously stabilized on 10mg of donepezil hydrochloride o...

Associated Conditions: Alzheimer's Disease (AD), Dementia With Lewy Body Disease, Dementia due to Parkinson's disease, Dementia of the Alzheimer's Type, Vascular Dementia (VaD), Moderate Alzheimer's Type Dementia, Severe Alzheimer's Type Dementia

Associated Therapies: -

Clinical Trials

Post-marketing Surveillance of Donepezil Hydrochloride - Investigation of Long Term Safety and Efficacy of Aricept as Well as Its Proper Use Information in Patients With Dementia With Lewy Bodies (DLB).

Completed

Conditions: Dementia With Lewy Body Disease

Interventions: Drug: Donepezil Hydrochloride

First Posted Date: 2015-05-19

Last Posted Date: 2018-07-11

Lead Sponsor: Eisai Co., Ltd.

Target Recruit Count: 591

Registration Number: NCT02448784

The Efficacy and Safety Study of High Dose Donepezil in Parkinson's Disease With Dementia

Phase 2

Conditions: Parkinson's Disease

Interventions: Drug: Donepezil

First Posted Date: 2015-04-14

Last Posted Date: 2015-08-06

Lead Sponsor: Inje University

Target Recruit Count: 150

Registration Number: NCT02415062

Locations: 🇰🇷
Inje university, busan paik hospital, Busan, Korea, Republic of

A Drug-Drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Lanabecestat
Drug: Donepezil
Drug: Simvastatin
Drug: Midazolam

First Posted Date: 2015-04-02

Last Posted Date: 2019-11-04

Lead Sponsor: AstraZeneca

Target Recruit Count: 82

Registration Number: NCT02406261

Locations: 🇺🇸
Covance Inc, Dallas, Texas, United States

Pharmacovigilance in Gerontopsychiatric Patients

Phase 3

Terminated

Conditions: Dementia
Depression
Schizophrenia
Psychosomatic Disorders
Anxiety Disorders

Interventions: Drug: Phenobarbital
Drug: Phenytoin
Drug: Carbamazepine
Drug: Oxcarbazepine
Drug: Valproic Acid
Drug: Lamotrigine
Drug: Topiramate
Drug: Gabapentin
Drug: Levetiracetam
Drug: Pregabalin
Drug: Lacosamide
Drug: Clonazepam
Drug: Biperiden
Drug: Levomepromazine
Drug: Fluphenazine
Drug: Perphenazine
Drug: Perazine
Drug: Thioridazine
Drug: Haloperidol
Drug: Melperone
Drug: Pipamperone
Drug: Bromperidol
Drug: Benperidol
Drug: Sertindole
Drug: Ziprasidone
Drug: Flupentixol
Drug: Chlorprothixene
Drug: Zuclopenthixol
Drug: Fluspirilene
Drug: Pimozide
Drug: Clozapine
Drug: Olanzapine
Drug: Quetiapine
Drug: Sulpiride
Drug: Tiapride
Drug: Amisulpride
Drug: Prothipendyl
Drug: Risperidone
Drug: Aripiprazole
Drug: Paliperidone
Drug: Diazepam
Drug: Oxazepam
Drug: Lorazepam
Drug: Bromazepam
Drug: Clobazam
Drug: Alprazolam
Drug: Hydroxyzine
Drug: Buspirone
Drug: Chloral Hydrate
Drug: Flurazepam
Drug: Nitrazepam
Drug: Triazolam
Drug: Lormetazepam
Drug: Temazepam
Drug: Midazolam
Drug: Brotizolam
Drug: Zopiclone
Drug: Zolpidem
Drug: Zaleplon
Drug: Melatonin
Drug: Clomethiazole
Drug: Diphenhydramine
Drug: Promethazine
Drug: Imipramine
Drug: Clomipramine
Drug: Opipramol
Drug: Trimipramine
Drug: Amitriptyline
Drug: Nortriptyline
Drug: Doxepin
Drug: Maprotiline
Drug: Amitriptyline oxide
Drug: Fluoxetine
Drug: Citalopram
Drug: Paroxetine
Drug: Sertraline
Drug: Fluvoxamine
Drug: Escitalopram
Drug: Tranylcypromine
Drug: Moclobemide
Drug: Mianserin
Drug: Trazodone
Drug: Mirtazapine
Drug: Bupropion
Drug: Venlafaxine
Drug: Reboxetine
Drug: Duloxetine
Drug: Agomelatine
Drug: Pyritinol
Drug: Piracetam
Drug: Donepezil
Drug: Rivastigmine
Drug: Galantamine
Drug: Memantine
Drug: Nicergoline
Drug: Acamprosate
Drug: Lithium

First Posted Date: 2015-03-02

Last Posted Date: 2018-02-28

Lead Sponsor: Hannover Medical School

Target Recruit Count: 407

Registration Number: NCT02374567

Locations: 🇩🇪
Bezirkskrankenhaus Augsburg, Augsburg, Germany
🇩🇪
Krankenhaus Hedwigshöhe, Berlin, Germany
🇩🇪
Hannover Medical School, Hannover, Germany

and more 2 locations

BI 409306 in Patients With Cognitive Impairment Due to Alzheimer's Disease.

Phase 2

Completed

Conditions: Alzheimer Disease

Interventions: Drug: Placebo
Drug: BI 409306
Drug: Donepezil

First Posted Date: 2015-01-14

Last Posted Date: 2018-11-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 329

Registration Number: NCT02337907

Locations: 🇫🇷
HOP La Pitié Salpêtrière, Paris, France
🇩🇪
Praxis Dr. med. Volker Schumann, Berlin, Germany
🇫🇷
HOP Pellegrin, Bordeaux, France

and more 57 locations

Donepezil Memory Preservation Post ECT

Not Applicable

Terminated

Conditions: Memory Impairment

Interventions: Drug: Donepezil
Drug: Placebo

First Posted Date: 2015-01-06

Last Posted Date: 2018-07-06

Lead Sponsor: Porter Adventist Hospital

Target Recruit Count: 12

Registration Number: NCT02331771

Locations: 🇺🇸
Porter Adventist Hospital, Denver, Colorado, United States

Effect of Electroacupuncture Combined With Donepezil for Treating Alzheimer's Disease

Phase 2

Conditions: Cognitive Impairment

Interventions: Procedure: acupuncture
Drug: donepezil

First Posted Date: 2014-12-03

Last Posted Date: 2017-05-16

Lead Sponsor: Guang'anmen Hospital of China Academy of Chinese Medical Sciences

Target Recruit Count: 334

Registration Number: NCT02305836

Locations: 🇨🇳
Guang'an Men Hospotal Affiliated to China Academy of Chinese Medical Sciences, Beijing, China

The Impact of Arousal Threshold in Obstructive Sleep Apnea

Phase 4

Completed

Conditions: Obstructive Sleep Apnea

Interventions: Drug: Donepezil
Drug: placebo

First Posted Date: 2014-10-15

Last Posted Date: 2019-08-08

Lead Sponsor: University of California, San Diego

Target Recruit Count: 44

Registration Number: NCT02264353

Locations: 🇺🇸
University of California, San Diego, San Diego, California, United States

Multicenter Evaluation of Memory Remediation After TBI With Donepezil

Phase 3

Active, not recruiting

Conditions: Memory Deficits
Traumatic Brain Injury

Interventions: Drug: Placebo
Drug: Donepezil

First Posted Date: 2014-10-03

Last Posted Date: 2024-08-06

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 160

Registration Number: NCT02255799

Locations: 🇺🇸
TIRR Memorial Hermann, Houston, Texas, United States
🇺🇸
Indiana University, Indianapolis, Indiana, United States
🇺🇸
Spaulding Rehabilitation Hospital, Charlestown, Massachusetts, United States

and more 1 locations

Effects of Donepezil on Regional Cerebral Blood Flow Following Aneurysmal Subarachnoid Haemorrhage

Phase 2

Terminated

Conditions: Aneurysmal Subarachnoid Hemorrhage
Delayed Cerebral Ischemia
Delayed Neurological Deficit
Vasospasm

Interventions: Drug: Donepezil

First Posted Date: 2014-08-21

Last Posted Date: 2017-09-11

Lead Sponsor: St George's, University of London

Target Recruit Count: 19

Registration Number: NCT02222727

Locations: 🇬🇧
St George's University of London, London, United Kingdom

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy